TBG Diagnostics Limited Inked A Deal With Zhangsha ZhangYe Medical- What You Need to Know

TBG Diagnostics Limited (ASX: TDL) develops, manufactures and markets nucleic acid test kits and offers related services. The company is mainly into the manufacture of molecular diagnostics instruments. The company has its various research & development centers which are located in the United States of America, Taiwan, and China. The company has got its facilities ISO 13485 registered in Xiamen, China. This facility serves the clinical labs of both, hospitals as well as the autonomous reference labs, blood centers and bone marrow registry labs across the globe. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

On 17 December 2018, the company announced that it has inked a pact via its subsidiary named TBG Biotechnology Xiamen, to acquire the Zhangsha ZhangYe Medical Laboratory Corp (“ZhangYe”). The target company typically provides medical laboratory testing services to hospitals and various other communities. The company is based in the city of Zhangsha in Hunan Province, Republic of China.

To acquire a 100% stake in ZhangYe, the company will discharge the consideration in the form of shares. These shares will constitute 42.10% of the of TBG Xiamen, which will be transferred to the founding shareholders of the target company, i.e., Zhangsha ZhangYe Medical Laboratory Corp.

One of the parties in the agreement is a private equity firm incorporated in China, named Dongyuan Huaxin (Beijing) Capital Management Co Ltd (“Dongyuan”). This PE firm will provide for the capital investment in the TBG Xiamen operations. As per the underlying agreement with the Dongyuan, shares constituting 11.25% of the TBG Xiamen’s share capital shall be issued to the subject private equity firm against a cash consideration of the RMB 10,679,283. This sum shall be reinvested by the P.E firm in the TBG Xiamen. This funding shall be utilized by the TBG Xiamen to expand its laboratories and molecular diagnostic capabilities, expanding sales capabilities & increasing TBG Xiamen’s distribution and sales channels by leveraging off the networks and relationships of ZhangYe and Dongyuan.

With the help of these agreements, the company intends to leverage the competence & capabilities of these organizations, so as to develop the synergies between each of the businesses of ZhangYe, Dongyuan, and the TBG Xiamen businesses. This pact would also lead to the expansion of TBG Xiamen Business further, into the regions of China & Asia Pacific.

Post the conclusion of these transactions; the company will continue to hold the 46.65% of the equity in the TBG Xiamen & the TBG Xiamen will hold a 100% stake in the ZhangYe. This would effectively mean that the company will indirectly hold an Interest of 46.65% in Zhang Ye.

Meanwhile, the share price of the company has fallen by 37.14 percent in the past six months as on 12 December 2018. TDL’s shares traded at $0.045, up by 2.273% & with a market capitalization of circa $9.57 Million as on 17 December 2018 (AEST 1:44 PM).


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report